Advanced search
Publication Cover
Current Medical Research and Opinion Volume 23, 2007 - Issue 6
Submit an article Journal homepage
236
Views
22
CrossRef citations to date
0
Altmetric
Original Article

Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge

Francis S. Mah University of Pittsburgh School of Medicine, Pittsburgh, PA, USACorrespondence[email protected]
,
Lanny J. Rosenwasser National Jewish Medical and Research Center, Denver, CO, USA
,
William D. Townsend Advanced Eye Care, Canyon, TX, and University of Houston College of Optometry, Houston, TX, USA
,
Jack V. Greiner Schepens Eye Research Institute and Harvard Medical School, Boston, MA, USA
&
George Bensch Health Through Research, Stockton, CA, USA
Pages 1445-1452 | Accepted 16 Apr 2007, Published online: 18 May 2007

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Eugene McLaurin, Mark Bergmann, Abhijit Narvekar, Adeniyi Adewale, Paul Gomes & Gail Torkildsen. (2017) Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. Clinical Ophthalmology 11, pages 1089-1097.
Read now
Ka Wai Kam, Li Jia Chen, Noel Wat & Alvin L. Young. (2017) Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. Ocular Immunology and Inflammation 25:5, pages 668-682.
Read now
Alexei Gonzalez-Estrada, Keerthi Reddy, Ves Dimov & Frank Eidelman. (2017) Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. Expert Opinion on Pharmacotherapy 18:11, pages 1137-1143.
Read now
Gail Torkildsen, Abhijit Narvekar & Mark Bergmann. (2015) Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model. Clinical Ophthalmology 9, pages 1703-1713.
Read now
Paramdeep S Bilkhu, Shehzad A Naroo & James S Wolffsohn. (2015) Treatment of ocular allergies: nonpharmacologic, pharmacologic and immunotherapy. Expert Review of Ophthalmology 10:3, pages 257-266.
Read now
Tuba Celik & Elif Betul Turkoglu. (2014) Comparative Evaluation of Olopatadine 0.01% Combined Fluorometholone 0.1% Treatment Versus Olopatadine 0.01% Combined Ketorolac 0.4% Treatment in Patients with Acute Seasonal Allergic Conjunctivitis. Current Eye Research 39:1, pages 42-46.
Read now
Alan G Kabat, David B Granet, Dina Amin, Maria J Tort & Michael S Blaiss. (2011) Evaluation of olopatadine 0.2% in the complete prevention of ocular itching in the conjunctival allergen challenge model. Clinical Optometry 3, pages 57-62.
Read now
Rengin Aslıhan Kurt, Ömür Ucakhan-Gündüz & Kaan Gündüz. (2010) Olopatadine 0.1% and 0.2% ophthalmic solution for the management of ocular allergy. Expert Review of Ophthalmology 5:3, pages 287-296.
Read now
Arthur B Epstein, Peter T Van Hoven, Alan Kaufman & Warner W Carr. (2009) Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clinical Ophthalmology 3, pages 329-336.
Read now
Shilpi Pradhan, Kumar Abhishek & Francis Mah. (2009) Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects. Expert Opinion on Drug Metabolism & Toxicology 5:9, pages 1135-1140.
Read now
Eiichi Uchio. (2008) Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clinical Ophthalmology 2:3, pages 525-531.
Read now
Mark B Abelson & Paul J Gomes. (2008) Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opinion on Drug Metabolism & Toxicology 4:4, pages 453-461.
Read now

Articles from other publishers (10)

Sophia Linton, Lubnaa Hossenbaccus & Anne K. Ellis. (2023) Evidence-based use of antihistamines for treatment of allergic conditions. Annals of Allergy, Asthma & Immunology.
Crossref
Hee-Jung Lee, Hyun Min Lim, Jing-Hui Feng, Ju Mi Lee, Jeong Tae Lee & Hong-Won Suh. (2022) Antinociceptive effect of N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide on different pain models in mice. Brazilian Journal of Pharmaceutical Sciences 58.
Crossref
Leonard Bielory & Dovid Schoenberg. (2019) Emerging Therapeutics for Ocular Surface Disease. Current Allergy and Asthma Reports 19:3.
Crossref
Rui-fen Liu, Xiao-xuan Wu, Xiao Wang, Jing Gao, Jun Zhou & Qi Zhao. (2017) Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study. International Forum of Allergy & Rhinology 7:4, pages 393-398.
Crossref
Stacey Ackerman, Lisa M. Smith & Paulo J. Gomes. (2016) Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Therapeutic Advances in Chronic Disease 7:1, pages 52-67.
Crossref
Robin L. Thurmond, Kayvan Kazerouni, Sandra R. Chaplan & Andrew J. Greenspan. 2015. Pharmacology of Itch. Pharmacology of Itch 257 290 .
E Carstens & Tasuku AkiyamaRobin Thurmond, Kayvan Kazerouni, Sandra Chaplan & Andrew Greenspan. 2014. Itch. Itch 143 192 .
Paramdeep S. Bilkhu, James S. Wolffsohn & Shehzad A. Naroo. (2012) A review of non-pharmacological and pharmacological management of seasonal and perennial allergic conjunctivitis. Contact Lens and Anterior Eye 35:1, pages 9-16.
Crossref
Mark B. Abelson, James T. McLaughlin & Paul J. Gomes. (2011) Antihistamines in Ocular Allergy: Are They All Created Equal?. Current Allergy and Asthma Reports 11:3, pages 205-211.
Crossref
. (2008) Current World Literature. Current Opinion in Allergy & Clinical Immunology 8:5, pages 489-497.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.